Latest news

Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary...

Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay...

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has...

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by...

The financing was led by Lord Moynihan of Chelsea alongside The Future Fund, with support from existing investors Funding will support...

Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary...

Published in Cardiovascular News, Dr Stephen Hoole, Chief Investigator of our BIOPATTERN trial and Consultant Cardiologist at Royal...

PlaqueTec receives the UK’s MHRA approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

What is the relationship between protein concentration at site of coronary atheroma and fibrous cap thickness?